Astrazeneca (AZN) EPS (Basic) (2009 - 2026)

Astrazeneca's EPS (Basic) history runs 18 years deep, the most recent figure standing at $7.94 for Q1 2026.

• In Q1 2026, EPS (Basic) fell 23.33% year-over-year to $7.94; the TTM figure through Mar 2026 stood at $12.66 (down 6.12% YoY), while the FY2025 annual figure was $6.6, up 45.37% from the prior year.
• EPS (Basic) was $7.94 for Q1 2026 at Astrazeneca, up from $1.5 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $10.35 in Q1 2025 to a low of $0.23 in Q2 2022.
• Historically, EPS (Basic) has averaged $1.97 across 5 years, with a median of $1.16 in 2023.
• The sharpest annual moves came in 2022 and 2025: EPS (Basic) sank 73.41% in 2022, then jumped 634.26% in 2025.
• A 5-year view of EPS (Basic) shows it stood at $0.58 in 2022, then gained by 6.9% to $0.62 in 2023, then surged by 56.45% to $0.97 in 2024, then soared by 54.64% to $1.5 in 2025, then surged by 429.21% to $7.94 in 2026.
• The last three EPS (Basic) figures came in at $7.94 (Q1 2026), $1.5 (Q4 2025), and $1.64 (Q3 2025), per Business Quant data.